- About
- Advertise
- Contact Us
- Editorial Staff
- Editorial Advisory Board
- Ethics Policy
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2020 MJH Life Sciences™ and Chromatography Online. All rights reserved.
UHPLC analysis of challenging MAbs
May 8, 2020
Sponsored Content - EU
This application note using YMC-Triart Bio C4 shows a robust separation at high temperatures of 3 commercially available MAbs: Ofatumumab, Palivizumab, and Panitumumab.